NanoMedU RNA Vaccine


T Cell Engineering

with Lipid Nanoparticles

On-demand course for convenient self-paced access.


Delivering exogenous genes encoding engineered T Cell receptors or gene editing nucleases is an essential step in creating engineered CAR T cell therapies. Learn how lipid nanoparticles (LNPs) – used in RNA medicines and vaccines – can be applied in your research to engineer primary human T Cells for developing future cell therapies.

Learning Objectives

 • Understand how and why RNA and LNPs are revolutionizing cell therapy

 • Learn the fundamentals of non-viral lipid nanoparticle gene delivery, how LNPs are made, how they work, and how they are used in a variety of applications

 • Learn how to rapidly and easily make mRNA-LNPs and how to apply them to transfecting primary human T cells in the cell therapy workflow

LNP for Cell Therapy

Who Should Attend

• Leaders in both academia and industry

• University Professor, Post Doc, Research Associate, Students in cell therapy

• Principal Scientist, Technology Leader, R&D Scientist with familiarity with cell therapy and electroporation or viral vectors seeking to understand LNPs and their applications in cell therapy

What's Included

• Certificate of completion

• 12 months access to on-demand content

• 2-hours recorded classroom-style lecture

• Recorded in-lab demonstration of RNA-LNP preparation and application in ex-vivo T cell culture

• Knowledge test


Register for T Cell Engineering with Lipid Nanoparticles through Cytiva






You can find many more online learning courses at Cytiva.


Shell Ip, PhD

Client Learning & Scientific Content Manager

Viet Anh Nguyen Huu, PhD

USCAN Director of FAS

Shell Ip

Dr. Ip has served in various technical communication and training roles in Precision NanoSystems since 2015. His postdoctoral and doctoral research focused on lipid-based nanoparticles for cancer theranostics at the University of Toronto.

Viet Anh Nguyen

Dr. Nguyen Huu devised formulations for ocular drug delivery and studied mechanisms of age-related eye disorders during his time at the UCSD. He has extensive expertise in formulation techniques including polymers, small molecules and proteins, as well as experience in analytical instrumentation and assays to characterize these constructs.

Reka Geczy, PhD

Scientist II

Reka Geczy
Dr. Geczy holds a PhD in Pharmaceutical Sciences from the University of British Columbia. After her postdoc at the University of Copenhagen, she joined Precision NanoSystems where she and her team are developing lipid nanoparticle compositions for cell therapy, currently focusing on CAR T therapies.

Guest Webinar

Sandy Tretbar, PhD

Group Leader at Fraunhofer Institute for Cell Therapy and Immunology (IZI)

Sandy Tretbar

Dr. Tretbar combines her long-standing RNA research experience with cell therapy development in immuno-oncology to investigate mRNA-based cell and gene therapies for the treatment of cancer and various other diseases.